

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-26 (Cancelled)


27 (New). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (1)

formula (1)



wherein R¹ represents the following formula (1-1):

formula (1-1)




wherein R³ represents alkyl or alkenyl and R⁴ represents alkyl; and

R^2 represents hydrogen, or α -galactose, α -glucose, α -mannose, α -glucosamine, β -glucosamine or a combination thereof.


28 (New). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein R^5 represents R^{51} , R^{52} , R^{53} , R^{54} , R^{55} , R^{56} , R^{57} , R^{58} , R^{59} , R^{70} , R^{71} , R^{72} , R^{73} , R^{74} , R^{75} , R^{76} , R^{77} , or R^{78} ; and R^6 represents hydrogen, R^{62} , R^{63} , R^{64} , or R^{65} :


R^{51} :




R^{52} :




R^{53} :




R⁵⁴ :




R⁵⁵ :




R⁵⁶ :




R⁵⁷ :




R⁵⁸ :




R⁵⁹ :




R⁷⁰ :




R⁷¹ :




R⁷² :




R⁷³ :




R⁷⁴ :




R⁷⁵ :




R⁷⁶:




R⁷⁷:




R⁷⁸:




R⁶²:




R⁶⁴:



R⁶³:



R⁶⁵:



29 (New). A method of activating NKT cell which comprises administering the cell activator according to claim 27 to a mammal.

30 (New). A method of activating NKT cell which comprises administering the cell activator according to claim 28 to a mammal,

31 (New). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 27 to a mammal.

32 (New). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 28 to a mammal.

33 (New). A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 27 to a mammal.

34 (New). A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 28 to a mammal.

35 (New). A method of activating dendritic cell which comprises administering the cell activator according to claim 27 to a mammal.

36 (New). A method of activating dendritic cell which comprises administering the cell activator to claim 28 to a mammal.

37 (New). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 27 to a mammal.

38 (New). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 28 to a mammal.

39 (New). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 27 to a mammal.

40 (New). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 28 to a mammal.

41 (New). A method of activating NK cell which comprises administering the cell activator according to claim 27 to a mammal.

42 (New). A method of activating NK cell which comprises administering the cell activator according to claim 28 to a mammal.

43 (New). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 27 to a mammal.

44 (New). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 28 to a mammal.

45 (New). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 27 to a mammal.

46 (New). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 28 to a mammal.

47 (New). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 27 to a mammal.

48 (New). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 28 to a mammal.

49 (New). A method of inhibiting viral activity which comprises administering the cell according to claim 27 to a mammal.

50 (New). A method of inhibiting viral activity which comprises administering the cell activator according to claim 28 to a mammal.

51 (New). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 27 to a mammal.

52 (New). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 28 to a mammal.

53 (New). A method of accelerating NO production which comprises administering the cell activator according to claim 27 to a mammal.

In re of: 10/553,695

54 (New). A method of accelerating NO production which comprises administering the cell activator according to claim 28 to a mammal.